Family offices were active in Europe and Asia this week, steering capital into medtech, biotech and private wealth services.
Sept. 29 – French medical device company CARMAT announced an update on its ongoing receivership procedure, naming the family office of Pierre Bastid as the preferred buyer. Bastid, CARMAT’s chairman, had previously provided €1.3 million in cash to support operations. The court is expected to review and decide on the proposed takeover in early October. (Business Wire)
Sept. 30 – Nanyang Biologics Pte. Ltd., an AI-driven drug discovery company, entered into a business combination agreement with RF Acquisition Corp. II in a $1.5 billion transaction to pursue a U.S. listing. The deal includes strategic investment from private family office backers supporting the biotech firm’s expansion into global markets. (PR Newswire)
Oct. 2 – Opera, whose majority owner is Pula, the family office of Stephen Lansdown, agreed to acquire Accuro, a trust and private office company. The acquisition extends Opera’s expansion strategy in private wealth and fiduciary services, backed by family office ownership. (Accuro)